Compare Merck & Co., Inc. (MRK) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Oatly Group AB - ADR — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Oatly Group AB - ADR trades at $9.21 (market cap $308.50M). The key difference: Merck & Co., Inc. is far larger — about 995.9× Oatly Group AB - ADR's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| MRK | OTLY | |
|---|---|---|
Market Cap | $307.25B | $308.50M |
Sector | Health | Consumer Staples |
52-Week High | $129.52 | $18.54 |
52-Week Low | $77.60 | $8.03 |
Enterprise Value | $350.66B | $806.12M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Oatly (OTLY) trades at $9.05, down 9.86% in the last session, with a neutral technical signal. The company shows modest revenue growth to $862M in 2025 but continues to report significant losses with a -17.06% net margin. Cash flow remains negative at -$35M, though improving from previous years. Recent news highlights new product launches and upcoming Q2 2026 earnings on July 22.
The outlook remains challenging with persistent losses and high debt levels creating financial strain. Analyst sentiment is mixed with 44% buy ratings but 50% hold, reflecting uncertainty about profitability timeline. Key risks include cash burn sustainability and competitive pressure in the plant-based beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
